ABT-450, a potent inhibitor of the HCV NS3/4A protease, is coadministered with 100 mg of ritonavir to improve ABT-450 plasma levels and half-life, permitting dosing once-daily.9 ABT-333 is a nonnucleoside NS5B polymerase inhibitor. A recent pilot study involving patients with HCV genotype 1 infection who received 12 weeks of treatment with ABT-450/r, ABT-333, and ribavirin showed rates of sustained virologic response 12 weeks after treatment of 93 to 95 percent among previously untreated patients and 47 percent among individuals who hadn’t had a reply or who had experienced only a partial response to prior therapy with peginterferon and ribavirin.10 The addition of a potent third direct-acting antiviral agent, the NS5A inhibitor ABT-267, may improve efficacy in patients for whom a poor response is predicted, including anyone who has not had a reply to prior therapy.This annual publication supplies the only comprehensive report on all AIDS vaccine medical trial activity worldwide. AMERICA, United Kingdom, Peru and Sweden began new trials in 2006 as well. A number of these trials had been sponsored by fresh research groups, including the Karolinska Institute in Sweden, St. George’s University of London and the Moscow Institute of Immunology. Related StoriesNew study may offer approaches for developing toxoplasma-inactivated vaccineSinovac Dalian receives acceptance to start human scientific trials of varicella vaccine candidateBasic study for developing toxoplasma vaccine underwayAll of the brand new trials that started last year were either Phase I or Stage I/II trials made to evaluate the protection and immunogenicity of the applicant vaccines.